September 1st, 2015|
Patients undergoing surgical procedures often need assistance in maintaining their core body temperature while under anesthesia. However, the defective medical device lawyers at Ferrer, Poirot & Wansbrough say new studies show one popular medical device used to keep patients warm may be putting their safety at risk.
The Bair Hugger™ Inflatable blanket fills with warm air to keep a patient’s body temperature from dropping to a dangerous level. In fact, it’s so popular, as many as 80 percent of hospitals in the U.S. utilize the device.
While the device may be effective in keeping patients warm, research shows it can increase a patient’s chances of developing an infection. A study published in the The Bone and Joint Journal found that patients who underwent a procedure utilizing the Bair Hugger™ may face up to a 380 percent increase in the chance of serious infection.
These injuries have resulted in some victims filing Bair Hugger™ hospital infection lawsuits. The victims claim they were not warned about the risks posed by the blanket.
According to Reuters, attorneys for the victims in some of these cases have filed a motion to move certain claims to the U.S. District Court for Minnesota.
At Ferrer, Poirot & Wansbrough, we are aware of the serious damages defective medical devices can cause, and our staff is hopeful that the decision reached in the Bair Hugger™ hospital infection lawsuits will help bring closure to victims and their families.
June 16th, 2015|
Painkillers can be vital to the care and treatment of those suffering from many injuries or diseases. However, the number of adverse health events involving these drugs continues to increase each year. In fact, the Centers for Disease Control and Prevention reports that painkiller overdoses accounted for more fatalities in 2013 than gunshot wounds and car accidents combined.
The painkiller overdose lawyers at Ferrer, Poirot & Wansbrough explain the federal government is hoping that a better infrastructure of prescription drug monitoring programs will reduce the number of drug injuries that involve painkillers each year.
Reports from The Post and Courier explain the American Medical Association (AMA) is calling for states to improve and build on prescription drug monitoring programs by ensuring they can effectively collect and share patient data. The AMA is also encouraging each state to ensure funding is available for these programs.
The hope is that these measures will help doctors examine the risks and benefits of prescribing painkillers to patients.
At Ferrer, Poirot & Wansbrough, we are aware of how dangerous prescription painkillers can be, and our drug injury lawyers are hopeful these new policies can help reduce the number of injuries and fatalities associated with this type of medication.
November 12th, 2013|
November 12, 2013
When a new drug is going to be introduced to the market, it must first be meticulously tested so that the U.S. Food and Drug Administration (FDA) can decide on what conditions the medication should be approved to treat. The Drug Injury Lawyers with Ferrer, Poirot & Wansbrough explain that due to a serious risk of injury, it is highly illegal and unethical for drug manufacturers to market their products for the treatment of conditions for which the medication is not approved.
Despite laws against the practice, “off-label marketing” still sometimes occurs. According to an article published by The Street, the FDA cited the Chief Executive Officer for Aegerion Pharmaceuticals, Marc Beer, recently for such an offense. Reports indicate that Beer made statements during news interviews that his company’s cholesterol-lowering medication, Juxtapid, can help prevent heart attacks and extend the lives of patients suffering from a disease known as hypercholesterolemia. This genetic condition causes the patient to build up dangerous levels of cholesterol in their blood stream.
The FDA stated that the medication was approved based strictly on trials that the drug lowered patient’s cholesterol levels, and that statements regarding the prevention of heart attacks or extending patient lives were unfounded.
The law firm’s team of Personal Injury Attorneys are aware of the serious harm off-label marketing of drugs can cause patients. That is why the firm urges anyone who was prescribed a medication by a doctor that was not approved to treat their condition discuss their legal rights with an attorney.
May 8th, 2012|
May 8, 2012
A new study shows that many medical mistakes may occur because of poor communication between patients and attending hospital staff. According to The Chicago-Tribune, medical mistakes that resulted in patient health complications were more than twice as likely to happen in hospitals that didn’t have translators for non-English speaking patients than those that did.
Researchers examined records from 57 families that visited two pediatric hospitals that participated in the study. All of the families spoke primarily Spanish, but only 20 families received the help of a professional translator. Ten other families had no assistance communicating with hospital staff, while the remainder used a family member or bilingual member of the hospital’s staff. Results showed that 12 percent of communication mistakes when a professional translator was used could have resulted in health risks, versus the 22 percent of risky communication errors that were made when a non-professional translated.
Training also played a part in how many mistakes were made during translation. Researchers found that interpreters with more than 100 hours of training were far less likely to make mistakes than those with less training.
Medical Malpractice Attorneys see all too often the devastating results of mistakes that poor communication between hospital staff led to. That is why the Personal Injury Lawyers with Ferrer, Poirot & Wansbrough suggest always asking questions of your doctor and medical staff before receiving treatment or beginning a new regimen of medications.
August 5th, 2010|
Those who have dealt with drug injuries associated with controversial medications like Avandia may appreciate what some medical professionals are recommending.
According to Reuters, risky drugs need a simpler process to ensure patients’ safety when it comes to protecting them from drug injuries.
The process for protecting patients from drug injuries associated with risky drugs known as REMS (risk evaluation and mitigation strategies) should have less paperwork and be more consistent, say drug makers and pharmacy representatives.
Right now patient information packets that come with medications are the most common form of protection against drug injuries from prescription medication.
However, drug makers and pharmacy representatives are recommending more studies with high-risk medications during the drug making process. They also advocate the same safety warnings and process for similar drugs with the potential for the same time of drug injuries.
Have you ever suffered a drug injury? Tell Ferrer, Poirot & Wansbrough Attorneys At Law about it.